Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Enerzair Breezhaler | indacaterol glycopyrronium mometasone furoate | Asthma maintenance, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecentriq & Avastin | Atezolizumab & Bevacizumab | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Oxervate | cenegermin | Neurotrophic keratitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeomin | incobotulinumtoxinA | Chronic sialorrhea associated with neurological disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inrebic | fedratinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 20, 2024